Enflonsia / clesrovimab-cfor for prevention of RSV Lower Respiratory Tract Disease in Neonates and Infants as of February 2026
MARA Rating Company
February 28, 2026
Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
